Articles tagged with Tuberculosis
A streamlined TB diagnosis approach using a single sputum sample and rapid results proved feasible in rural Uganda, increasing treatment initiation rates. The method uses fluorescence microscopy for quick analysis and GeneXpert testing for accurate results, with 73% of patients diagnosed correctly.
The lateral flow urine lipoarabinomannan assay (LF-LAM) shows an average sensitivity and specificity of 45% and 92% in HIV-positive people with TB symptoms. However, its sensitivity is higher in individuals with low CD4 cell counts, making it a potential tool for early diagnosis and treatment.
Charles Daley, Irina Petrache, and James Crapo receive awards for their work on tuberculosis diagnosis, women in pulmonary medicine, and COPD research respectively. The American Thoracic Society honors their contributions to improve patient outcomes in respiratory diseases.
Researchers identified a novel tuberculosis pathogen, Mycobacterium mungi, transmitted through environmental urine and anal gland secretions in banded mongooses. This discovery radically changes the understanding of TB transmission, with implications for wildlife and livestock health.
Research finds TB transmission in mongooses occurs through social behavior, with scent marks and urine allowing pathogen spread. Smaller social groups are most threatened by the disease.
Researchers discovered that TB bacteria trick immune cells into building up fat to feed them, rather than destroying them. This finding provides new insights into the mechanisms of TB infection and potential treatment approaches using antisense oligonucleotides.
New data shows an estimated 340,000 Europeans developed TB in 2014. While progress has been made in reducing new cases, high rates of multidrug-resistant TB and TB affecting vulnerable groups continue to challenge elimination efforts. Targeted interventions for marginalized populations are crucial to successfully tackling TB
Scientists at Oxford University have identified biomarkers that could indicate TB risk and provide clues to assess the effectiveness of potential new vaccines. The discovery was made using immune correlates, also known as biomarkers, which can be measured in the blood.
Scientists have discovered a new way to inhibit the growth of Mycobacterium tuberculosis by using modified cholesterol as an energy source. This breakthrough holds promise for the development of new treatments for tuberculosis, a highly infectious lung disease that kills one person every 21 seconds.
Researchers at UCLA and Shanghai Jiao Tong University have developed a new feedback system control technique to pinpoint the best possible drug-dose ratios for treating tuberculosis. This approach has identified promising combination treatments that can kill bacteria much faster than standard regimens, potentially shortening treatment ...
Researchers found that curcumin successfully removes Mycobacterium tuberculosis from infected cells in culture by inhibiting the activation of nuclear factor-kappa B. The study suggests a potential new treatment for drug-resistant tuberculosis that could be less prone to resistance development.
Researchers in South Africa are conducting a medical trial focused on controlling tuberculosis (TB) epidemics. The trial uses a novel approach that combines intensified household tracing and screening for TB and HIV using rapid molecular technologies.
Research reveals that smoking damages macrophages, leading to TB infection and worsening its progression. The impaired cells can't recycle debris, becoming 'clogged up' and less effective at fighting infection.
Researchers identified biological markers in blood samples from latently infected individuals that can predict the risk of developing active TB. These biomarkers may enable targeted therapies to prevent illness in high-risk individuals.
Experts from the European Respiratory Society call for improved TB care for refugees to control and eliminate the disease. They emphasize the need for quality surveillance, monitoring, evaluation, and research among this group of people to prevent a rise in new cases.
Researchers aim to collect and analyze 100,000 TB samples to create a database of MDR-TB genes, enabling faster diagnosis using whole genome sequencing. The project, CRyPTIC, will take around five years to complete and could potentially save lives by providing the right treatment.
A large clinical trial found that treating HIV patients at risk for tuberculosis with TB drugs does not save more lives. Simple TB screening and isoniazid preventive therapy were well-tolerated and resulted in similar survival rates compared to a four-drug TB treatment.
A randomized clinical trial found that using four drugs for TB does not improve survival rates over isoniazid therapy in advanced HIV/AIDS patients. The study validates the World Health Organization guidelines for prescribing isoniazid to vulnerable patients.
A study published in PLOS Pathogens suggests that HIV infection disrupts the immune response to Mtb, making it harder for the body to control active TB. Researchers found that early HIV infection diminishes a specific component of the immune response called IL-10, leading to a weaker defense against Mtb.
Researchers found that adding statins to standard drug treatment reduced the time to clear tuberculosis infection by 35% in infected mice. The study suggests that repurposing statin drugs could accelerate TB treatment and improve public health outcomes.
A new study published in The Lancet suggests that a low-cost, urine test to diagnose tuberculosis among patients with HIV could save thousands of lives per year in sub-Saharan Africa. The test, which provides results in 25 minutes and costs $2.66, showed an absolute reduction of 4% in TB death rate among patients with HIV.
A study found that HIV patients in Africa with a certain genetic variant have a 63-percent lower chance of developing tuberculosis than those without the variant. This discovery may lead to the development of new TB treatments effective for both HIV-positive individuals and the general population.
A collection of papers from global health experts argues that investing in new health tools, delivery innovations, and disease control strategies can avert 10 million deaths annually. The collection focuses on five conditions disproportionately affecting the world's poorest people.
A GW chemistry professor is leading a team of researchers to identify enzyme inhibitors as possible medications for devastating diseases like malaria and tuberculosis. The five-year, $2.6 million grant will focus on designing small molecule inhibitors that can stop the production of key enzymes necessary for pathogen survival.
A new methodology developed at Rice and Rutgers universities helps scientists understand how biochemical networks control biological responses. The approach predicted novel interactions in bacteria that cause tuberculosis, revealing a potential mechanism for the disease's survival.
Researchers at Stanford University School of Medicine have developed a simple blood test that can accurately diagnose active tuberculosis, setting the stage for a significant transformation in disease control. The test works on ordinary blood samples and distinguishes patients with active TB from those with latent TB or other diseases.
Researchers at Trinity College Dublin have made a significant discovery in how our immune system responds to TB, enabling the development of more effective vaccines and personalized therapies. The study highlights the importance of the protein Mal in cell signaling and its impact on responses to Interferon Gamma.
Scientists have uncovered the 3D structure of an enzyme crucial for Mycobacterium tuberculosis survival. This discovery could lead to the development of new compounds targeting the ketol-acid reductoisomerase (KARI) enzyme, which is only present in bacteria and plants.
Researchers at Vanderbilt University Medical Center have discovered a new compound that is more effective against the tuberculosis enzyme and maintains activity against resistant forms. The findings could lead to a more effective treatment for the deadly disease, which killed 1.5 million people in 2014.
TB cases decreased in recent US entrants from Mexico, Philippines, India, Vietnam, and China due to decreases in population and TB case rates. Non-recent entrants also experienced an unexpected decline, highlighting the need for strategies impacting both groups to further reduce TB morbidity.
A new study published in the American Journal of Respiratory and Critical Care Medicine found that the most commonly used TB test failed to accurately diagnose tuberculosis in up to 50% of pregnant women who are HIV+. The researchers developed a new method to identify which women carrying latent TB infection are most likely to develop ...
A study found that up to 66.8% of households experience catastrophic health expenditure for tuberculosis care, with the poorest households bearing the brunt. Expanding universal healthcare and increasing reimbursement rates could lower these costs and have positive economic effects.
Researchers found that fluoroquinolones interact with an enzyme in TB germs, but not as strongly as thought. They discovered a new way to make the drugs more potent by targeting broken DNA within the gyrase complex. This could lead to improved treatments for multidrug-resistant TB and other bacterial infections.
Clinical research experts discuss various topics, including the impact of personalized genomic data on healthcare systems, strategies to combat multidrug-resistant tuberculosis, and population approaches to reduce diabetes incidence. They also highlight the need for improved cancer diagnosis and treatment for neurodegenerative diseases.
A prospective cohort study found that receiving an average of at least six potentially effective drugs per day was associated with a 36% greater likelihood of responding to treatment. The inclusion of more drugs, particularly pyrazinamide, was also linked to improved sputum culture conversion rates.
Researchers discover FDA-approved medications with dual-action against bacterial energy production and specific enzymes, potentially reducing resistance. Such multitarget drugs could treat a range of infections, including tuberculosis and Staphylococcus aureus.
The La Jolla Institute will characterize immune responses to dengue virus and Mycobacterium tuberculosis with the HIPC grant. The research aims to identify effective gene signatures for vaccines against these diseases, which are major global health challenges.
A new, inexpensive, and quick method for detecting tuberculosis has been devised, using a nucleic acid amplification test on disposable electrochemical sensors. The modified test, which involves a colorimetric assay that changes to blue if the infection is present, can be performed with minimal equipment and expertise.
The study reveals high genetic diversity of TB strains in Ethiopia, suggesting that Europeans introduced a new wave of virulent strains. The findings contradict the long-held 'virgin soil hypothesis' and shed light on past epidemics of TB.
A new study from the University of Rochester found that early life exposures to toxic chemicals like PCBs and DDE reduce infants' responses to vaccines. The research, which analyzed blood samples from over 500 mother-infant pairs in eastern Slovakia, shows that even small changes can lead to long-term immune system dysfunction.
A computer model of tuberculosis has shown that daily antibiotic regimens are more effective than once or twice a week in preventing drug-resistant strains. The study suggests that increasing the number of doses and improving drug properties can lead to significant improvements in treatment success rates.
The study identified at least three different structural classes of compounds active against multidrug-resistant and extensively drug-resistant strains of tuberculosis. These new inhibitors target the reductive sulfur assimilation pathway, essential for the bacteria's survival in host defense systems.
A recent study has found that treating a parasitic worm infection can reduce lung damage and susceptibility to tuberculosis in mice. The research suggests that using inexpensive anti-parasitic drugs could be an effective way to prevent TB in areas where both infections are common.
A 2-year-old girl was diagnosed and treated for XDR TB, the first detailed account of a young child in the US. The successful treatment highlights the need for better understanding and creative approaches to pediatric tuberculosis.
Researchers have determined the structure of a key enzyme in Mycobacterium tuberculosis, which could lead to new drugs for the disease. The discovery provides a potential starting point for developing treatments that target this enzyme.
TB researchers propose a biosocial approach combining biomedical interventions with social actions to address root causes of the disease, which include poverty, malnutrition, and overcrowding. The strategy aims to reduce morbidity and mortality while alleviating poverty and promoting sustainable development.
Researchers at Tulane National Primate Research Center are working on a new tuberculosis vaccine by modifying Mycobacterium tuberculosis to lose stress response gene SigmaH. Monkeys vaccinated with the modified strain showed better resistance to infection and protective immune responses in their lungs.
A £3.5 million grant will fund a trial to determine whether a weekly vitamin D supplement can prevent tuberculosis (TB) in 5,400 primary schoolchildren in Cape Town. The trial aims to discover whether the supplement can reduce the risk of acquiring latent TB infection, which may develop into active TB later in life.
Research suggests that universal TB screening of immigrants to Canada is costly and inefficient, with most cases detected from a small number of high-risk countries. The study recommends targeting screening on immigrants from countries with high TB rates, rather than universally.
A study found that the majority of active TB cases in Canada were linked to immigrants from Afghanistan, China, India, Pakistan, Philippines, and Vietnam. This suggests that developed countries can focus on screening for TB in high-risk immigrants rather than screening all arrivals.
HIV-infected patients are excluded from early-phase clinical trials of new anti-tuberculosis drugs, resulting in slower development and potential drug interactions with antiretroviral therapy. Experts urge including HIV patients in relevant trials to accelerate development and address drug resistance.
A Phase 2a trial will assess the safety and immunogenicity of IDRI's TB vaccine candidate in 60 participants in South Africa, who have previously had active TB. The trial aims to reduce TB recurrence after treatment, a major threat to TB control programs.
A cluster randomized controlled trial found that electronic reminders via medication monitors and text messages improved tuberculosis treatment adherence, with non-adherent rates decreasing from 29.9% to 17.0%. The study suggests innovative approaches to improve TB treatment outcomes in remote areas.
A new study published in PLOS Medicine found that electronic reminders can significantly improve tuberculosis treatment adherence in China. Patients who received electronic medication monitors missed only 17% of their doses, compared to 29.9% for those with no reminders and 27.3% for those receiving text message reminders.
Researchers from Queen Mary University of London found declining numbers of Bovine TB infections in Scotland and Wales, while England's approach is unlikely to succeed. More frequent testing led to effective control of the disease, with a significant decline in infections.
Researchers have developed three new rapid tests for diagnosing drug-resistant tuberculosis (TB), which can be completed in as little as a day. The tests were found to be accurate in detecting resistance to most anti-TB drugs, with the molecular techniques showing superior performance.
A project in Togo saw a 10% drop in TB death rates by increasing the treatment success rate to 95%, while mortality dropped from 13% to 3%. The redesigned system improved coverage, quality, and patient participation, highlighting the importance of data analysis and skilled workforce.
Researchers have identified a novel virulence factor that could be ripe for drug development, targeting the electron transport process in TB. The discovery of MenJ, a gene essential for the organism's proliferation, offers hope for rapid treatment of the disease.
A new $1.45-million program will enhance the training of scores of Ghanaian researchers in new research methods, grant writing, ethics, and clinical care for TB and HIV patients.
Researchers found that ethoxzolamide inhibits TB's ability to detect acidic environments, effectively blinding the bacterium and allowing the immune system to attack. This compound could help shorten treatment duration and slow the emergence of drug resistance in TB.